Safusidenib (AB-218, DS-1001)
Sources
company_release, as of 2026-11-07
Nuvation Bio release (2026, exact date not captured; page timed out on 11.07.2026, values from search record and the 10.27 brief): safusidenib J201 Phase 2 update, n = 27, 250 mg BID, confirmed ORR 51.9%, 36-month PFS 79.1%, median follow-up 38.8 months; new G209 and G307 studies (company release)
Brief source I8
publication, as of 2026-11-07
Nuvation Bio release 08.20.2026: FDA Fast Track designation for safusidenib in IDH1-mutant glioma (search record)
Brief source I9
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT04458272
A Phase II Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-naive IDH1 Mutated WHO Grade II Glioma
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT05303519
A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07712757
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Safusidenib in Participants With Grade 2 Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07703436
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07832123
Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study
ClinicalTrials.gov API v2 record, retrieved 2026-11-07